期刊文献+

徐宜厚教授辨证治疗寻常型银屑病学术研究 被引量:9

Professor XU Yihou's Treatment of Psoriasis Vulgaris by Syndrome Differentiation
下载PDF
导出
摘要 [目的]总结徐宜厚教授治疗寻常型银屑病的学术观点和临床经验。[方法]通过跟师学习,分析研究徐宜厚老师治疗寻常型银屑病临床病案,从病因病机、辨证论治、经验用药等方面总结老师治疗寻常型银屑病的学术思想和临证经验,并举验案佐证。[结果]徐宜厚教授认为寻常型银屑病病因病机是外感六淫侵袭,肺胃气机不畅,气血运行受阻,肌肤失养;内伤七情以及饮食不节为主,日久化火,营血亏虚,外伤肌表,腠理毛窍闭塞,气滞血瘀。其将寻常型银屑病辨证分为风热证、血热证、血燥证、血瘀证,从解表祛风、凉血解毒、养阴润燥、化瘀解毒治疗用药,分别采用消风散、银花虎杖汤、养血润肤汤、黄芪丹参汤等加减。同时采用分期辨病,将寻常型银屑病分为进行期、退行期、静止期三期,病证结合,又结合外治法,药浴、软膏、针罐疗法等,临床治疗取得满意疗效。所举医案4则,体现了徐宜厚教授辨证论治寻常型银屑病,分别以祛风、凉血、养血、化瘀等方法治疗的思路,取得良好的疗效。。[结论]徐宜厚教授分期辨病,进行期宜驱邪法,退行期宜攻补兼施,静止期扶正固本或者滋阴护液。病证结合治疗寻常型银屑病有良好的临床疗效,充分体现了中医整体观念、辨证论治的精髓,其分期辨病、病证结合、辨病用药的学术观点及临床经验值得推广。 [Objective]To summarize Professor XU Yihou's academic views and clinical experience in the treatment of psoriasis vulgaris.[Methods]Through learning from the teacher,analyzing and researching XU Yihou's clinical psoriasis vulgaris cases,summarizing the academic thinking and clinical experience of the teacher in the treatment of psoriasis vulgaris from the aspects of etiology,pathogenesis,syndrome differentiation,treatment,and experience medications,and conducting trials evidence.[Results]Professor XU Yihou believes that the pathogenesis of psoriasis vulgaris is caused by exogenous six evils,causing poor lung and stomach Qi,blocked blood and running,and dying of the skin.Internal injuries,seven emotions and diet are not the main,long-term fire,blood deficiency,traumatic muscle surface,phlegm and sputum occlusion,Qi stagnation and blood stasis,the syndrome of psoriasis vulgaris is divided into wind-heat syndrome,using Xiaofeng powder.Blood heat syndrome,using Yinhuahuzhang soup addition and subtraction. Blood dryness syndrome,using Yangxue Moisturizing Soup addition and subtraction.Blood stasis syndrome,using Huangqi Danshen Decoction.The combination of disease and syndrome,combined with external treatment,medicated bath,ointment,needle and cupping therapy and other clinical treatments have achieved satisfactory results.And from the solution of hurricane,cooling blood detoxification,nourishing Yin and moistening,phlegm and detoxification treatment drugs,so as to achieve better clinical efficacy.[Conclusion]Prof.XU Yihou used staged disease differentiation and disease therapy to treat slow psoriasis vulgaris with good clinical curative effect,fully embodying the whole concept of TCM,the essence of syndrome differentiation and treatment,and distinguishing diseases in stages,combining disease and syndrome,and discriminating diseases and drugs.Academic perspectives and clinical experience are worth promoting.
作者 李波 吴美兰 曲刚 LI Bo;WU Meilan;QU Gang(Dalian,Dermatology Hospital,Dalian(116021);Dalian City Traditional Chinese Medicine Hospital)
出处 《浙江中医药大学学报》 CAS 2018年第11期911-914,共4页 Journal of Zhejiang Chinese Medical University
关键词 寻常型银屑病 辨证治疗 用药特点 名医经验 医案 徐宜厚 中医皮肤科 psoriasis vulgaris syndrome differentiation treatment medication features famous TCM doctors'experience medical records XU Yihou TCM dermatology
  • 相关文献

参考文献9

二级参考文献65

  • 1李常兴,张锡宝,吴志华.甲氨蝶呤与银屑病[J].岭南皮肤性病科杂志,2004,11(2):200-203. 被引量:39
  • 2Parisi R, Symmons DPM, Gfiffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence [ J ]. Journal of Investigative Dermatology, 2012, 133 (2) :377-385.
  • 3Kirby B, Griffiths CEM. Novel immune - based therapies for psoriasis [ J ]. British Journal of Dermatology, 2002,146 ( 4 ) : 546- 551.
  • 4Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis [ J ]. Expert opinion on investigational drugs,2012,21 (4) :473-487.
  • 5Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis[ J]. Dermatologic therapy,2009,22 ( 1 ) :56-60.
  • 6van den Berg WB, McInnes IB. Thl7 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics [ C ]//Seminars in arthritis and rheumatism. WB Saunders,2013,43(2) :158-170.
  • 7Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate - to - severe plaque psoriasis: a randomized, double - blind, placebo - controlled phase II dose ranging study [ J ]. British Journal of Dermatology,2013,168 (2) :412-421.
  • 8McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial[J]. Annals of the rheumatic diseases,2014, 73(2) :349-356.
  • 9Ren V, Dao Jr H. Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis [ J ]. Clinical, cosmetic and investigational dermatology ,2013,6:75.
  • 10Gordon K, Leonardi C, Braun D. Results after at least 52 weeks of open label treatment with ixekizumab, an anti-lL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis[J]. J Am Acad Dermatal,2014,70(5 Supplement 1).

共引文献52

同被引文献104

引证文献9

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部